RESULTS FROM A PHASE I/II TRIAL OF TINOSTAMUSTINE MONOTHERAPY IN ADVANCED SOLID TUMOURS (NCT03345485): SAFETY AND EFFICACY IN A SUBSET OF PATIENTS WITH ADVANCED OVARIAN CANCER (OVCA)

被引：0
|
作者：
Tinker, Anna V. [1 ]
Chugh, Rashmi [2 ]
Curigliano, Giuseppe [3 ]
Kummar, Shivaani [4 ]
Schneider, Reva [5 ]
Strauss, James [5 ]
Janik, Tomas [6 ]
Manamley, Nick [6 ]
Hilgier, Kasia [6 ]
Oaknin, Ana [7 ]
机构：
[1] BC Canc, Vancouver, BC, Canada
[2] Univ Michigan, Rogel Comprehens Canc Ctr, Ann Arbor, MI USA
[3] European Inst Oncol, IRCCS, Milan, Italy
[4] Oregon Hlth & Sci Univ, Portland, OR USA
[5] Mary Crowley Canc Res, Dallas, TX USA
[6] Mundipharma Res Ltd, Cambridge, England
[7] Hosp Univ Vall Hebron, Gynaecol Canc Programme, Vall Hebron Inst Oncol VHIO, Vall Hebron Barcelona Hosp Campus, Barcelona, Spain
来源：
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER | 2023年 / 33卷
关键词：
D O I：
10.1136/ijgc-2023-ESGO.526
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
163
引用
收藏
页码：A252 / A252
页数：1
相关论文
共 50 条
  • [21] Cabazitaxel in patients with advanced solid tumours: Results of a Phase I and pharmacokinetic study
    Dieras, V.
    Lortholary, A.
    Laurence, V.
    Delva, R.
    Girre, V.
    Livartowski, A.
    Assadourian, S.
    Semiond, D.
    Pierga, J. Y.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 (01) : 25 - 34
  • [22] Efficacy and safety results from GEICO 1205, a randomized phase II trial of neoadjuvant chemotherapy with or without bevacizumab for advanced epithelial ovarian cancer
    Garcia Garcia, Yolanda
    de Juan Ferre, Ana
    Mendiola, Cesar
    Barretina-Ginesta, Maria-Pilar
    Gaba Garcia, Lydia
    Santaballa Bertran, Ana
    Bover Barcelo, Isabel
    Gil-Martin, Marta
    Manzano, Aranzazu
    Rubio Perez, Maria Jesus
    Romeo Marin, Margarita
    Arqueros Nunez, Cristina
    Garcia-Martinez, Elena
    Gonzalez Martin, Antonio
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2019, 29 (06) : 1050 - 1056
  • [23] Safety and efficacy results from a phase I dose-escalation trial of Nintedanib in combination with Pembrolizumab in patients with advanced solid tumors (PEMBIB trial)
    Varga, Andreea
    Baldini, Capucine
    Martin-Romano, Patricia
    Hollebecque, Antoine
    Gazzah, Anas
    Bahleda, Rastislav
    Menis, Jessica
    Champiat, Stephane
    El-Dakdouki, Yolla
    Paoletti, Xavier
    Ribrag, Vincent
    Michot, Jean-Marie
    Rafie, Saloomeh
    Planchard, David
    Besse, Benjamin
    Massard, Christophe
    Soria, Jean-Charles
    Marabelle, Aurelien
    CANCER RESEARCH, 2018, 78 (13)
  • [24] Safety and efficacy results from a phase I dose-escalation trial of Nintedanib in combination with Pembrolizumab in patients with advanced solid tumors (PEMBIB trial).
    Varga, Andreea
    Baldini, Capucine
    Martin-Romano, Patricia
    Besse, Benjamin
    Planchard, David
    Champiat, Stephane
    Angevin, Eroc
    Hollebecque, Antoine
    Bahleda, Rastislav
    Gazzah, Anas
    Armand, Jean-Pierre
    Paoletti, Xavier
    Massard, Christophe
    Soria, Jean-Charles
    Marabelle, Aurelien
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [25] Safety profile and preliminary efficacy of capecitabine (Xeloda®) in combination with oxoliplatin in patients with advanced or metastatic solid tumours:: Results from a phase I study.
    Evans, J
    Tabernero, J
    Cassidy, J
    Sastre, J
    Eatock, M
    Baselga, J
    Bissett, D
    Regueiro, P
    Rubio, ED
    ANNALS OF ONCOLOGY, 2000, 11 : 51 - 51
  • [26] Safety and Tolerability of AZD0466 As Monotherapy for Patients with Advanced Hematological Malignancies. Preliminary Results from an Ongoing Phase I/II Trial
    Arslan, Shukaib
    Fleming, Shaun
    Jain, Nitin
    Martinelli, Giovanni
    Stein, Anthony S.
    Blachly, James S.
    Bajel, Ashish
    Curti, Antonio
    Marconi, Giovanni
    Fabbri, Giulia
    Marmor, Yotvat
    Sharma, Shringi
    Elgeioushi, Nairouz
    Couto-Francisco, Natalia
    Saeh, Jamal
    Tibes, Raoul
    Cader, Fathima Zumla
    Konopleva, Marina
    BLOOD, 2022, 140 : 9091 - 9093
  • [27] Preliminary results from a Phase II trial of EPO906 patients with advanced refractory ovarian cancer
    Kaye, S
    Oza, A
    Gore, M
    Huinink, W
    Smit, W
    Gibbon, D
    Miller, W
    Mull, R
    Chitale, K
    Rothermel, J
    EUROPEAN JOURNAL OF CANCER, 2002, 38 : S43 - S43
  • [28] Efficacy and safety results of FGFR1-3 inhibitor, tinengotinib, as monotherapy in patients with advanced, metastatic cholangiocarcinoma: Results from phase II clinical trial.
    Javle, Milind M.
    Mahipal, Amit
    Fonkoua, Lionel Aurelien Kankeu
    Fountzilas, Christos
    Li, Daneng
    Pelster, Meredith
    Liao, Chih-Yi
    Richards, Donald A.
    Deming, Dustin A.
    Younes, Mohamad Ahmad
    Mantry, Parvez
    Cohn, Allen Lee
    Kingsley, Ed
    Fan, Jean
    Peng, Peng
    Sun, Caixia
    Wang, Hui
    Hennessy, Katie
    Shan, Yujun
    Wu, Frank
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : 434 - 434
  • [29] Safety and Efficacy of Tinostamustine in a Subpopulation of Patients With Relapsed/Refractory Hodgkin Lymphoma From a Phase I Trial
    Sureda, Anna
    Pinto, Antonio
    Ghesquieres, Herve
    Morschhauser, Franck
    Tournilhac, Olivier
    Mutsaers, Pim
    Zijlstra, Josee M.
    De Filippi, Rosaria
    Hilgier, Kasia
    Manamley, Nick
    Janik, Tomas
    Zinzani, Pier Luigi
    HEMATOLOGICAL ONCOLOGY, 2025, 43 (01)
  • [30] Preliminary efficacy and safety of tinengotinib (TT-00420) monotherapy in Chinese patients (pts) with advanced solid tumors: Results from a phase Ib/II study
    Zhang, P.
    Gong, J.
    Guo, H.
    Han, W.
    Cao, B.
    Zhang, J.
    Niu, Z.
    Cheng, Y.
    He, C.
    Fan, J.
    Peng, P.
    Sun, C.
    Wang, H.
    Yu, Y.
    Zhu, Y.
    Wu, Y.
    Li, Q.
    Huang, P.
    Wu, F.
    Shen, L.
    ANNALS OF ONCOLOGY, 2023, 34 : S471 - S471
12345